BZ-30
BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3028405-31-1
- Formule: C14H13F6N3
- Masse moléculaire:337.26
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
BZ-30 (0.15-5 μM) reduces viral RNA levels by ≥99% in wild-type SARS-CoV-2-infected Vero E6 cells at the concentration of 5 μM, and exhibits dose-dependent antiviral activity[1].
BZ-30 (24 h) potently inhibits the effective replication of wild-type SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.65 μM[1].
BZ-30 (24 h) acts as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern in Vero E6 cells, with IC50 values ranging from 0.51 μM (Beta variant) to 12.37 μM (Omicron variant)[1].
BZ-30 can partially inhibit the endosomal entry of SARS-CoV-2 pseudovirus; its inhibitory effect is stronger in HEK293-ACE2 cells (up to 75%) compared with the 50% inhibition rate observed in HEK293-ACE2/TMPRSS2 cells[1].
BZ-30 (0-24 h) acts on the early stage of the wild-type SARS-CoV-2 life cycle in Vero E6 cells, and inhibits viral replication when administered within 2 h post-infection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Syrian Golden Hamsters (female, 6-8 weeks old, intranasally inoculated with 105 PFU of SARS-CoV-2)[1]
-
Dosage:15 mg/kg
-
Administration:i.p.; twice daily; 4 days (starting 8 h post-infection)
-
Result:Reduced viral load by log10 0.44 TCID50 per mg lung, corresponding to a 64% reduction in viral load.
Significantly reduced the lung-to-body weight ratio.
Maintained body weight comparable to the positive control remdesivir.
Lowered the cumulative histopathological lung score from 14 to 3.
Showed minimal alveolar and epithelial cell degeneration, with only occasional peri-vascular and peri-bronchiolar focal inflammatory cell infiltration.
Chemical Information
-
CAS No. 3028405-31-1
-
Masse moléculaire 337.26
-
Formule C14H13F6N3
-
SMILES
CC1(CCC1)NC2=NC3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3N2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BZ-30 Related Classifications
HY-183185 Related Classifications
Powered by Bioz